Vektor Medical, a medical technology company transforming cardiac arrhythmia care, today announced that it has won the 2026 MedTech Innovator Mid-Stage Grand Prize, receiving $200,000 in non-dilutive funding. The award recognizes the company’s achievements in developing and commercializing vMap®, its FDA-cleared, non-invasive arrhythmia localization technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109027466/en/
Vektor Medical celebrates being named the 2026 MedTech Innovator Mid-Stage Grand Prize Winner at The MedTech Strategist Innovation Summit in San Diego.
MedTech Innovator, the world’s largest accelerator of medical technology companies, selected its 2026 cohort from a competitive pool of 1,835 applicants worldwide. Vektor was named one of five Mid-Stage Grand Prize finalists, with the winner determined by a live audience vote following presentations and expert panel discussions at the MedTech Strategist Innovation Summit in San Diego on November 4, 2026.
“Being named the 2026 MedTech Innovator Mid-Stage Grand Prize Winner is an incredible honor and a significant milestone for Vektor Medical,” said Rob Krummen, CEO of Vektor Medical. “To be recognized among such an exceptional group of innovators working to advance healthcare is both humbling and deeply meaningful. This recognition is a testament to the passion, perseverance, and dedication of our team, and the progress we’re making toward transforming cardiac arrhythmia care. As adoption of vMap continues to grow, we’re excited to build on this momentum and bring the benefits of noninvasive arrhythmia mapping to more physicians and patients.”
Vektor developed vMap, the only FDA-cleared, non-invasive technology that uses standard 12-lead ECG data to localize arrhythmia source locations across all four chambers of the heart. By providing physicians with patient-specific information before invasive mapping, vMap supports more informed procedural planning and focused ablation strategies.
The recognition comes amid continued commercial and clinical progress for Vektor. With more than 4,500 procedures performed using vMap across the United States, the company continues to expand adoption of its technology while advancing clinical evidence and reimbursement pathways to support broader access.
The MedTech Innovator Mid-Stage Grand Prize recognizes companies demonstrating meaningful progress, strong commercial potential and the ability to transform patient care. The award provides Vektor with additional visibility across the global medtech community as the company continues to scale adoption of vMap.
About Vektor Medical
Headquartered in San Diego, Vektor Medical is redefining how arrhythmias are understood and treated. The company developed vMap®, the only FDA-cleared, non-invasive technology that uses standard 12-lead ECG data to localize arrhythmia source locations across all four chambers of the heart. By helping physicians identify arrhythmia sources more quickly and with greater accuracy, Vektor is working to improve procedural efficiency and expand access to effective treatment strategies. To learn more, visit www.vektormedical.com.
About MedTech Innovator
MedTech Innovator is the world’s largest accelerator of medical device, digital health, and diagnostic companies. Its mission is to improve human health by accelerating the growth of companies transforming patient care. MTI has been a catalyst for groundbreaking healthcare solutions, sourcing more than 20,000 applicants and fostering the growth of 957 graduates. Alumni have collectively raised $12 billion in follow-on funding, seen 66 acquisitions, and introduced 600+ products to the market, improving the health of millions worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261109027466/en/
Media gallery
